MobbleOpen in Mobble ⇢
Health · Drug development · published 2026-09-02 · via BioSpace

UniQure submits regulatory applications for AMT-130 in US and UK

Image via BioSpace
Image via BioSpace

UniQure has submitted a Biologics License Application to the US FDA for its investigational gene therapy AMT-130, targeting Huntington's disease. The company has also filed for approval in the United Kingdom, marking a potential first for this condition.

Read the full article at BioSpace →
Related stories
UniQure seeks FDA and UK approval for Huntington's gene therapy AMT-130 · Drug development
UK suspends Tavneos sales, UniQure files for Huntington's gene therapy approval · Drug development
Pancreatic cancer drug wins FDA approval, marking shift toward targeted therapy · Cancer research
AbbVie's etentamig succeeds in Phase 3 myeloma trial, cutting progression risk by 60% · Drug development
This summary is AI-generated and original to Mobble; the linked article is the authoritative source. Original headline: “UniQure files for FDA, UK approval of first gene therapy for Huntington's disease.” Browse more stories.